Uncategorized

The latest from Cogstate, leaders in optimizing the measurement of cognition

Cogstate to Present at the NORD Rare Diseases and Orphan Products Breakthrough Summit

October 11, 2018

Presentation to Outline Innovative Methodology for Developing Indication-Specific Outcome Measures in Rare Disease Clinical Trials New Haven, CT – October 11, 2018: The cognitive science company, Cogstate Ltd (ASX.CGS) today announced a presentation entitled, “Methodology for Development of Indication-Specific Outcome Measures in Rare Disease Trials: An Innovative Research Approach” will be delivered at the National […]

Cogstate announces European approval for Healthcare offering

June 4, 2018

BOSTON – June 4, 2018: The cognitive science company, Cogstate, today announced that its Healthcare Division has received CE Mark approval for its Cognigram™ digital cognitive assessment system. “Cogstate Healthcare is excited about this significant regulatory milestone and we look forward to joining the fight against brain health challenges in European markets,” said Frank Cheng, […]

Cogstate Scientists Contribute to New Research Framework to Redefine Alzheimer’s Disease

April 17, 2018

A new research framework for understanding Alzheimer’s disease has been developed and released by the Alzheimer’s Association (AA) and the National Institute on Aging (NIA).  This framework proposes an important shift in the definition of Alzheimer’s disease from being founded on the presence and nature of symptoms to one based on the identification and characterization of pathologic changes in the […]

Cogstate Establishes Rare Disease and Pediatric Center of Excellence

April 5, 2018

Dr. Pam Ventola appointed to lead implementation as Senior Science Director, Rare Disease and Pediatric Center of Excellence New Haven, CT – April 5, 2018: The cognitive science company, Cogstate Ltd (ASX.CGS) today announced the establishment of a Rare Disease and Pediatric Center of Excellence to lead all activities related to the selection and administration […]

Eric Siemers, M.D., Named Distinguished Medical Adviser at Cogstate

February 27, 2018

Siemers will provide expert advice for Cogstate in neurodegeneration research New Haven, CT – February 27, 2018: The cognitive science company, Cogstate Ltd (ASX.CGS) today announced the appointment of Eric Siemers, M.D., as Distinguished Medical Adviser. Dr. Siemers will provide expert advice for Cogstate’s pharmaceutical customers with regard to the design of clinical trials of […]

International publications validate Cogstate technology’s clinical value in detecting Postoperative Cognitive Dysfunction (POCD)

February 12, 2018

BOSTON – February 13, 2017: From the Interdisciplinary Conference on Orthopedic Value Based Care sponsored by the American College of Perioperative Medicine, Cogstate announced that the Cogstate Brief Battery™ has now been shown to be useful for guiding decision making about cognitive outcomes in older adults awaiting or undergoing surgery. Cogstate Brief Battery is the proprietary […]

Cogstate Strengthens Global Clinical Science Expertise with the Appointment of Senior Vice President, Dr. Chris Edgar

February 9, 2018

New Haven, CT – February 9, 2018: The cognitive science company, Cogstate Ltd (ASX.CGS) today announced the addition of Dr. Chris Edgar, Senior Vice President, Clinical Science to its global scientific leadership team. Dr. Edgar joins the Cogstate team in Europe as an experienced leader in cognitive assessment and clinical endpoint strategy. He will provide […]

Global Alzheimer’s Platform Foundation Selects Cogstate for Industry-First Rater Certification Program

January 24, 2018

Cogstate to Support Rater Training and Certification Program to Enable Accelerated Study Start-up in Alzheimer’s Disease Clinical Trials New Haven, CT – January 24, 2018: The cognitive science company, Cogstate Ltd (ASX.CGS) today announced it has been chosen by the Global Alzheimer’s Platform (GAP) Foundation to support GAP’s rater certification program (RCP) that will significantly […]

Cogstate Announces First U.S. Deployment of the Cognigram™ System at the University of Notre Dame

October 11, 2017

BOSTON – October 11, 2017: The cognitive science company, Cogstate today announced the commercial deployment of its Cognigram™ digital cognitive assessment system at the University of Notre Dame. This placement represents the first Cognigram system commercial implementation in the United States, following the recent FDA notification that the Company can begin marketing the system in […]

Cogstate receives positive FDA notification regarding medical device regulatory submission

July 27, 2017

Company to launch COGNIGRAMTM digital cognitive testing tool in U.S. healthcare market Boston, MA – July 27, 2017: The cognitive science company, Cogstate today announced that its healthcare division has received notification from the U.S. Food and Drug Administration (FDA) that the Company’s 510(k) submission (K171658) for the COGNIGRAMTM cognitive assessment system has been reviewed […]

Pilot Study Demonstrates Working Memory Training May Be Effective For Children With Neurofibromatosis

June 27, 2017

While neurofibromatosis often appears in children as visible spots, freckles or tiny bumps, the genetic disorder can also cause learning disabilities, including problems with attention, working memory, inhibition and planning. Up to 40% of children with neurofibromatosis type 1 (NF1) are diagnosed with Attention Deficit/Hyperactivity Disorder (ADHD). These symptoms can often cause issues at home […]

Cogstate Selected as Preferred Provider to Lilly’s Alzheimer’s Disease Platform

May 17, 2017

Company to Deliver Novel Solutions to Ensure High-quality Neuropsychological Measures in Clinical Trials New Haven, CT – May 17, 2017: The cognitive science company, Cogstate Ltd (ASX.CGS) today announced it has been chosen as the preferred provider to the global healthcare leader, Eli Lilly and Company, to support their Alzheimer’s disease platform with solutions to ensure […]

Cogstate Announces New Executive Appointments For Clinical Trials And Healthcare Business Units

November 30, 2016

The cognitive science company, Cogstate Ltd (ASX.CGS) announced today two key appointments to executive positions. George Hunnewell has been named Chief Operating Officer of Cogstate and President of the Cogstate Clinical Trials division. Hunnewell, who previously served as Corporate Vice President, Clinical Research Services for Parexel International Corporation, will be responsible for the company’s worldwide […]

Cogstate and Clinical Ink Deliver Enhanced Tablet-Based eCOA for CNS Clinical Trials

October 24, 2016

New Haven, CT & Philadelphia, PA– October 25, 2016: Cognitive science company, Cogstate Ltd (ASX.CGS) and Clinical Ink, the leading provider of eSource and patient engagement technologies, today announced they have formalized their long-standing relationship with a strategic alliance that delivers enhanced tablet-based neuropsychological assessments for CNS clinical trials. The alliance combines, in a single […]

Cogstate Computerized Battery Effective For Long-Term Monitoring of Cognitive Side Effects in Pediatric Leukemia Patients

October 20, 2016

Children with acute lymphoblastic leukemia (ALL) often battle neurocognitive deficits as a result of their radiation or chemotherapy treatment. During treatment and sometimes up to two years after treatment, their quality of life is affected by impairments in attention, processing speed and executive functioning. While many pediatric leukemia studies have identified possible counter measures later […]

1 2